The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial to assess the safety and pharmacokinetics of afatinib and weekly vinorelbine in patients with advanced solid tumors.
Antoine Hollebecque
No relevant relationships to disclose
Rastislav Bahleda
No relevant relationships to disclose
Yann Berge
No relevant relationships to disclose
Christophe Massard
No relevant relationships to disclose
Martina Maria Uttenreuther-Fischer
Employment or Leadership Position - Boehringer Ingelheim
Helene De-Montserrat
Employment or Leadership Position - Boehringer Ingelheim
Inga Tschoepe
Employment or Leadership Position - Boehringer Ingelheim
Jean-Charles Soria
Honoraria - Boehringer Ingelheim; Roche
Jean-Pierre Delord
No relevant relationships to disclose